A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four months sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in patients with prostate cancer
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 26 Jun 2012 Additional trial location (Portugal) added as reported by European Clinical Trials Database.
- 10 Jan 2007 New trial record.